Portal de Periódicos da CAPES

Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg and 200/50 mg twice daily in HIV-negative volunteers

2010; Oxford University Press; Volume: 66; Issue: 3 Linguagem: Inglês

10.1093/jac/dkq468

1460-2091

Akil Jackson, A.D. Hill, Rebekah Puls, LJ Else, Janaki Amin, David Back, Enmoore Lin, Saye Khoo, Sean Emery, Roland Morley, Brian Gazzard, Marta Boffito,

HIV-related health complications and treatments

Data suggest that some licensed antiretroviral doses could be reduced. We assessed the safety, tolerability and pharmacokinetics of lopinavir/ritonavir at doses of 400/100, 200/150 and 200/50 mg twice daily in HIV-negative volunteers (http://clinicaltrials.gov/ct2/show/NCT00985543).